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Abstract
Background: Most cost-effectiveness analyses in the context of cervical cancer prevention involve the use of
mathematical models to simulate HPV infection, cervical disease and prevention strategies. However, it is common
for professionals who would need to perform these analyses to not be familiar with the models. This work
introduces the Online Cost-Effectiveness ANalysis tool, featuring an easy-to-use web interface providing health
professionals, researchers and decision makers involved in cervical cancer prevention programmes with a useful
instrument to conduct complex cost-effectiveness analyses, which are becoming an essential tool as an approach
for supporting decision-making that involves important trade-offs.
Results: The users can run cost-effectiveness evaluations of cervical cancer prevention strategies without deep
knowledge of the underlying mathematical model or any programming language, obtaining the most relevant
costs and health outcomes in a user-friendly format. The results provided by the tool are consistent with the
existing literature.
Conclusions: Having such a tool will be an asset to the cervical cancer prevention community, providing
researchers with an easy-to-use instrument to conduct cost-effectiveness analyses.
Keywords: Cervical cancer screening, Markov chain model, Cost-effectiveness, Online tool, cancer prevention,
Decision making
Background
Health care resources are scarce and therefore, their effi-
cient allocation is a priority for policy-makers. To guide
the process of decision making in this context, cost-
effectiveness analysis is an essential tool. When the avail-
able prevention strategies are multiple and potentially
synergic, as occurs in the context of cervical cancer,
cost-effectiveness analysis becomes critical to ensure the
optimal allocation of resources [1].
Cervical cancer and other cancer and noncancer dis-
eases are caused by or related to human papillomavirus
(HPV), a common sexually transmitted infection [2]. In
fact, it is estimated that more than 80% of sexually active
men and women will acquire an HPV infection by age
45 years [3]. HPV infections are asymptomatic in most
cases, although some can lead to the formation of cer-
vical abnormalities called cervical intraepithelial neopla-
sia (CIN), which can lead to cervical cancer. This cancer
is one of the most prevalent cancers among women
worldwide, especially in less developed countries [4].
Cervical cancer can be prevented by means of screening
to find precancerous lesions (secondary prevention) -so
they can be treated- or by HPV vaccination (primary
prevention) to prevent infection from some of the most
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frequent high-risk types. Several countries are imple-
menting a combined prevention strategy including both
vaccination and screening, which is recommended on
the basis of current evidence, although details may vary.
The World Health Organization (WHO) recommends
that countries should implement HPV vaccination in
preadolescent girls if it is affordable, cost-effective, and
sustainable and that achieve the highest possible cover-
age [5]. However, there are still many challenges faced
by cervical cancer prevention programmes [6]. Cur-
rently, most cost-effectiveness analyses focused on the
evaluation of cervical cancer prevention strategies are
conducted by means of mathematical models that simu-
late the natural history of HPV and cervical cancer.
These complex models must integrate data from various
sources and should be effectively calibrated to health tar-
gets. The tool presented in this work is based on a Mar-
kov model that simulates the natural history of HPV
infection and subsequent cervical disease. The model
computes relevant health and economic outcomes as
cases averted, life expectancy (LE) from 11 years, reduc-
tion in the lifetime risk of CC, life years saved, quality-
adjusted life years (QALYs), net health benefits, and life-
time costs. In this paper we present OCEAN, a new easy
to use web application that allows for cost-effectiveness
analyses based on a prespecified mathematical model to
be run. This model is described in detail in [7]. The tool
and a video tutorial illustrating its usage are available at
https://iconcologia.shinyapps.io/HECR-OCEAN/. Despite
the tool’s ease of use and design, thought to be usable for
inexperienced users, the authors are available to provide
guidance in case it is needed.
Implementation
The tool is based on a previously described Markov
model [7]. The details of this model are also available as
supplementary material.
The OCEAN tool
The tool provides an easy-to-use web interface to con-
duct cost- effectiveness analyses. The sample data avail-
able from the OCEAN tool, and in particular the yearly
regression and progression transition probabilities be-
tween health states were extracted from a literature re-
view [8–12]. The web interface is based on the shiny
package [13] for R [14]. Its main screen is divided into
two panels, one focused on the calibration process and
the second on the cost-effectiveness analyses.
Calibration process
The goal of the calibration part is to provide the user
with a reliable transition probability matrix adjusted to
the specific setting, to feed the Markov model that will
be used in the cost-effectiveness analyses. The calibra-
tion panel requires the following inputs:
 Number of simulations: Number of simulated
cohorts.
 Number of simulations to keep: Number of
simulated cohorts that will be kept and used in the
cost-effectiveness analyses. Among all simulated co-
horts, the best ones (the matrices producing the out-
comes that minimize the differences with respect to
target HPV infection prevalence and CC incidence).
All these simulated cohorts will be used to obtain
the cost-effectiveness outputs if the Uncertainty
Level (see the inputs for the cost-effectiveness ana-
lysis in the next subsection) is not zero, and stored
each in one sheet on the same file. This allows the
tool to generate several estimates for each cost-
effectiveness output (one per matrix) and therefore
to generate and display confidence intervals.
 Percentage of change: Maximum allowed difference
between two equivalent transition probability
matrices.
 Mortality: Checkbox that should be ticked if
mortality data are available and it is wanted to be
used in the calibration process.
 Transition probability matrix: Starting values for the
transition probability matrix. A general transition
probability matrix will be used if no user-specific
matrix is provided.
 Incidence file: Registered cervical cancer incidence
for the specific setting, without any medical
intervention (rate × 100,000 women). It is uploaded
in a spreadsheet file and will be used as a target in
the calibration process.
 Prevalence file: Registered HPV16/18 infection
prevalence for the specific setting. It is uploaded in
an Excel file and will be used as a target in the
calibration process.
 Mortality file: Registered mortality due to cervical
cancer for the specific setting (rate × 100,000
women). It is uploaded in an Excel file and will be
used as a target in the calibration process if
mortality is checked.
An Excel file including all calibrated matrices can be
downloaded and used for the cost-effectiveness analyses.
The default transition probability matrix is calibrated to
Spanish data, but the users could upload their own HPV
prevalence, incidence and mortality data and calibrate
the transition probabilities matrix to their own settings.
Cost-effectiveness analysis
The cost-effectiveness panel of the tool requires the fol-
lowing inputs:
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 Number of different scenarios: The number of
scenarios to be analyzed in the current session. Note
that each scenario may include none (no
intervention or natural history), one or more
prevention strategies (screening alone, vaccination
alone or vaccination followed by screening).
 Matrix of transition probabilities between different
health states without medical intervention:
Transition probability matrix obtained in the
previous panel or uploaded by the user. Additionally,
the included default file can be used.
 Medical costs and utility coefficients: An Excel file
containing the treatment direct medical and
nonmedical costs, indirect costs and utility
coefficients. An example can be downloaded from
the tool.
 Discount rate: Discount rate to be applied to health
and costs (undiscounted results can be obtained by
setting the discount rate to 0).
 Uncertainty level: It is known that the results of
cost-effectiveness analyses are affected by a certain
degree of uncertainty at different levels. They can be
reflected in the OCEAN tool by using more than
one transition probability matrix to feed the Markov
model. If a file with several sheets is used and the
uncertainty level is set to 0, an averaged matrix will
be used, and only point estimates will be reported. If
the uncertainty level is set to a value α between 0
and 50, all the matrices are used, and the outcomes
obtained from each one are recorded. Then, the
mean and percentiles α2 and 1 −
α
2 for each outcome
are calculated and reported.
The considered prevention strategies that can be se-
lected for each scenario (alone or combined) include the
following:
 Natural history: No prevention strategy is
considered in this scenario, which reproduces the
natural history of HPV infection and cervical cancer.
If this option is chosen, the other options disappear.
 Screening: Several screening scenarios can be
defined, depending on test (cytology, HPV DNA
test or visual inspection), frequency (every 1–10
years), targeted ages, and switch age from
cytology to HPV testing. The screening coverage,
positive predictive value, sensitivity and costs are
read from the Excel file loaded as “Scenario-
specific values”. The structure of this file can be
explored by downloading the example file from
the tool. Screening may be organized (all women
are screened with the selected frequency) or
opportunistic (the screening period is variable).
To set an opportunistic screening scenario, an
additional Excel file specifying the proportion of
women screened each period is required.
 Vaccination: Preadolescent girls are successfully
vaccinated at the age of 11 years with one, two or
three doses of the vaccine against HPV types 16 and
18. Efficacy and coverage are set by the user and
vaccination costs are read from the Excel file loaded
as “Scenario-specific values”. The structure of this
file can be explored by downloading the example file
from the tool. Currently, only bivalent vaccine is
considered but it is planned that quadrivalent and
nonavalent vaccines will be available soon as well.
An Excel file with all generated results can be down-
loaded, including information about the inputs used to
generate those particular results.
Results
This section reproduces the cost-effectiveness analysis
reported in [7] using the OCEAN tool. The goal is to
mimic some of the cervical cancer prevention strategies
available in Spain, particularly comparing conventional
cytology to HPV testing, with and without vaccination.
All the input files used in this section are available as
supplementary materials. First, we can use the calibra-
tion part of the tool to check whether the input matrix
we use fits the Spanish registered data in a reasonable
manner (Tables S2 and S3 show the considered HPV in-
fection prevalence and cervical cancer incidence).
Through the graphs provided by the calibration part of
the OCEAN tool, it can be seen whether the input
matrix fits the targeted values. The output calibrated
matrices are also useful to introduce some random noise
(determined by the percentage of change and the num-
ber of simulations to keep), allowing us to incorporate
some uncertainty into the final outcomes, providing the
researcher with a more realistic picture of the cost-
effectiveness results. The output matrices from the cali-
bration part can be used as input for the cost-
effectiveness analysis part, where the details on the dif-
ferent prevention strategies considered are set. The out-
put from the tool shows the user that the input matrix is
well calibrated (Fig. 1).
Once a -or multiple- calibrated transition probability
matrix that feeds the Markov model has been generated
in the calibration part, it is time for the cost-
effectiveness analysis. In this example, we will consider
the following prevention strategies:
 Natural history: The first scenario considers no
prevention strategy.
 Vaccination alone: In this scenario, preadolescent
girls are successfully vaccinated at the age of 11
years with three doses of the vaccine against HPV
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types 16 and 18. The analysis was carried out
assuming favorable vaccine with 70% efficacy and a
lifelong duration of vaccine immunity to prevent
cervical lesions caused by HPV 16 and 18 among
uninfected women. No cross-protection against
other high-risk HPV types was assumed. The uptake
is set to 70%.
 Screening alone: Assuming that screening with
conventional cytology starts at 25 years of age and
continues until age 65, this strategy considers that
primary organized HPV DNA testing is performed
in women older than 30 years of age with cytology
triage for positive women. Women are screened in a
5-year period. For women younger than 30 years of
age, cytology is the reference test. The sensitivity
and specificity of HPV DNA testing to detect CIN2+
are 90.5 and 93.0%, respectively, and 90.5 and 91.9%
for cytology after a positive HPV test [15]. Screening
coverage is 70%. On the basis of a study carried out
in Spain, we assume that the sensitivity and
specificity of cytology to detect CIN2+ are 38.2 and
97.8%, respectively [15].
 Combined vaccination and screening: In this
scenario, we implement vaccination in girls aged 11
years, followed by screening according to the
parameters and assumptions described previously
for vaccination and screening alone.
For all the scenarios, a 3% discount rate for health out-
comes and costs and a 5% uncertainty level are applied.
The unitary costs used in this example are reproduced
in Table S4. Figure 2 is a screenshot from the tool with
the proper inputs corresponding to each described
scenario.
The output tables reported by the tool can be seen in
Fig. 3 and are available as supplementary material in the
same format in which can be downloaded from the tool
(Table S5).
The results tables from Fig. 3 show that the health and
cost outcomes are very similar to those reported in [7].
Fig. 1 Example of the calibration panel and outputs for the age-specific cervical cancer incidence and the age-specific HPV16/18 prevalence
compared to the observed data. The output is based on the 5 best-fitting (the matrices producing the outcomes that minimize the differences
with respect to target HPV infection prevalence and CC incidence) simulations out of 10 demanded with a 10% change
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Fig. 2 Example of inputs and parameters for four different scenarios: no intervention or natural history, vaccination alone, screening alone and
combined vaccination and screening
Fig. 3 Example of output tables as reported by the tool for four different scenarios
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A figure reproducing Fig. 3 from [7] is available as sup-
plementary material (Fig. S2), also leading to the ex-
pected results.
Conclusions
Carrying out complex cost-effectiveness analyses can be
challenging for many researchers involved in cervical
cancer prevention and for public health decision makers.
The OCEAN tool provides an easy-to-use interface, re-
quiring only a working internet connection and fairly
available input information to allow its users to compare
the most common cervical cancer prevention strategies
worldwide using their specific parameters. There is a
lack of robust, rigorous, accessible tools allowing users
to conduct reliable cost-effectiveness analyses, as these
analyses may play an important role in deciding public
health policies in cervical cancer. We consider that the
outputs of the OCEAN tool are of potential usefulness to
the public health and cervical cancer prevention com-
munities, but with some constraints.
In general, it is known that the mathematical models
used in cost-effectiveness analyses are subject to uncer-
tainty at different levels [16], and therefore, the results
provided by the tool (even setting the uncertainty level
over zero) must be taken with caution. In particular, the
calibration process of the OCEAN tool does not include
optimization routines, although they have been recently
recommended in the literature [1] due to time limita-
tions on the on-line interface.
Assessing the impact of uncertainty in the results, ei-
ther through statistical analysis or through sensitivity
analysis, is recommended by recent guidelines on health
economic evaluation [17, 18]. The OCEAN tool facili-
tates the task of handling uncertainty through determin-
istic and probabilistic sensitivity analyses [19–21], so the
implications on the cost-effectiveness analysis can be
easily examined.
Several extensions of the software are currently
planned. For instance, other vaccines (quadrivalent and
nonavalent) will be included, and the vaccination admin-
istration period will be extended to other ages, including
catch-up vaccination and male vaccination. Using a
static underlying model also has some relevant limita-
tions such as not capturing herd immunity benefits due
to HPV vaccination, although this Markov model can
handle complex screening strategies and it is known that
static models improve the transparency and robustness
of the results compared to dynamic models [22]. To
overcome this issue, more sophisticated models based
on microsimulation will be included in the near future.
Other HPV-related diseases (genital warts, recurrent
respiratory papillomatosis and other cancer locations
such as the vulva, vagina, penis, anus and oropharynx)
will also be considered in upcoming versions of the tool.
Availability and requirements
The OCEAN tool is accessible with only a working
internet connection. Sample input files are available
from the tool website and are ready to be used.
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